Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma

Prominin-1 (CD133) has been suggested as a potential marker of cancer stem cells (CSCs) in various cancer types. The aim of this study was to compare CD133 expression between adenoma cells, colorectal adenocarcinoma (CRAC) cells, and tumor microenvironment cells (TMEs) in terms of the adenoma-carcin...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-08, Vol.38 (8), p.4819-4826
Main Authors: Lee, Yong-Moon, Yeo, Min-Kyung, Seong, In-Ock, Kim, Kyung-Hee
Format: Article
Language:English
Subjects:
AC133 Antigen - biosynthesis
Adenocarcinoma
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenoma
Adenoma - pathology
Aged
Biomarkers, Tumor - biosynthesis
Calcium channels
Cancer
Carcinogenesis
Carcinogenesis - pathology
Carcinogens
Cell Nucleus - metabolism
Colorectal cancer
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
Cytoplasm - metabolism
Disease-Free Survival
Female
Humans
Immunohistochemistry
Localization
Male
Medical prognosis
Metastases
Metastasis
Stem cells
Tumor Microenvironment
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prominin-1 (CD133) has been suggested as a potential marker of cancer stem cells (CSCs) in various cancer types. The aim of this study was to compare CD133 expression between adenoma cells, colorectal adenocarcinoma (CRAC) cells, and tumor microenvironment cells (TMEs) in terms of the adenoma-carcinoma sequence and to investigate the clinicopathological value of CD133 expression in CRACs as a prognostic marker. A total of 58 adenomas and 132 primary and 27 metastatic CRACs were examined for CD133 expression by immunohistochemistry. The cytoplasmic and nuclear expression levels of CD133 were scored by semi-quantitative methods. Adenomas showed significantly lower cytoplasmic and nuclear CD133 expression than CRACs (p
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.12792